Abstract
Experiment 1 examined whether microinjections of morphine (1 microg in 0.5 microl over 1 min x 2 pairings) into 13 different CNS sites produced a conditioned place preference (CPP). Injections into the lateral ventricles (LV), ventral tegmental area (VTA), or periaqueductal gray (PAG) produced a CPP; injections 1 mm dorsal to the PAG or VTA, or into the caudate putamen, medial frontal cortex, hippocampus, lateral nucleus of the amygdala, lateral hypothalamus, pedunculopontine tegmental nucleus, posterior hypothalamus, ventral palladium, or nucleus accumbens septi (core or shell) did not. In Experiment 2, morphine 0.2 microg produced a CPP when injected into the VTA but not in the PAG, while 5.0 microg was effective in both sites. The CPP induced by systemic morphine (4 mg/kg x 1 pairing) was blocked by naloxone methiodide (NM) injected (2 nmol in 0.5 microl) into the VTA. PAG injections of 2 nmol reduced, and 5 nmol NM eliminated, the CPP. The results confirm that morphine injections into the VTA or the PAG are rewarding, that blockade of opioid receptors in either site disrupts a morphine-induced CPP, and that the VTA is more sensitive to both effects.
Citations
Mar 12, 2013·Behavioural Brain Research·Lauren V RitersSharon A Stevenson
Mar 26, 2013·Behavioural Brain Research·Sara KarimiAbbas Haghparast
Mar 30, 2004·Brain Research·Mohammad-Reza ZarrindastMajid Jafari-Sabet
Aug 7, 2002·European Journal of Pharmacology·Manizheh KaramiHedayat Sahraei
Aug 9, 2002·European Journal of Pharmacology·Azam GholamiMohammad-Reza Zarrindast
Oct 24, 2002·European Journal of Pharmacology·Mohammad Reza ZarrindastHedayat Sahraei
Dec 25, 2002·European Journal of Pharmacology·Azam GholamiAli Haerri-Rohani
Jan 16, 2003·Neuropharmacology·Tamzin L RipleyDavid N Stephens
Sep 6, 2002·Pharmacology, Biochemistry, and Behavior·Elizabeth M ByrnesRobert S Bridges
Oct 12, 2002·Pharmacology, Biochemistry, and Behavior·Ameneh RezayofAli-Haeri-Rohani Haeri-Rohani
Dec 14, 2002·Pharmacology, Biochemistry, and Behavior·Mohammad Reza ZarrindastHassan Ghoshouni
May 20, 1998·Pharmacology, Biochemistry, and Behavior·K B Franklin
Apr 24, 2001·Pharmacology & Therapeutics·M NaritaT Suzuki
Jun 18, 1999·Behavioural Brain Research·W J McBrideS Ikemoto
Jan 8, 1999·Peptides·G A OlsonA J Kastin
Dec 15, 2000·Progress in Neurobiology·T M Tzschentke
Jan 1, 1999·Progress in Neurobiology·T M Tzschentke
Aug 4, 2012·PloS One·Elyssa B MargolisHoward L Fields
May 23, 2013·PloS One·Shervin GholizadehSteven R Laviolette
Nov 22, 2013·PloS One·Xavier RezaiDominique Massotte
Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·A J Blood, R J Zatorre
Apr 2, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·David J RademacherGloria E Meredith
May 20, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anna K RadkeJonathan C Gewirtz
Jun 10, 2011·EMBO Molecular Medicine·Amy Chang Berger, Jennifer L Whistler
Sep 13, 2011·Psychopharmacology·J E RobinsonC J Malanga
Jun 7, 2012·Psychopharmacology·Thomas C JhouSatoshi Ikemoto
Aug 14, 2012·Psychopharmacology·James P Burkett, Larry J Young
Nov 28, 2012·Proceedings of the National Academy of Sciences of the United States of America·Edita NavratilovaFrank Porreca
Jan 25, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·You-Qing CaiZhizhong Z Pan
May 30, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Patrick ArchieLorenzo Cohen
Nov 8, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Susan F VolmanMary Kay Lobo
Nov 28, 2013·Cellular and Molecular Neurobiology·Yasaman RazaviAbbas Haghparast